For example, inhibition of FGF19 in CCND1-amplified tumors (11q13 amplification) using anti-FGF19 antibodies has been shown to be an effective therapy for hepatocellular carcinoma (HCC), and the blockage of its FGFR receptors has shown promising clinical results in FGF19/FGF4+ HCC [29,30,31]. This evidence concerns the gene FGF4 and hepatocellular carcinoma.